Read by QxMD icon Read

Medical Oncology

Barbara Diletto, Nicola Dinapoli, Silvia Chiesa, Gian Carlo Mattiucci, Vincenzo Frascino, Carmelo Anile, Cesare Colosimo, Vincenzo Valentini, Mario Balducci
OBJECTIVES: Treatment of oligometastatic patients is a current challenge in radiation oncology. Aim of this study is to define a dose-response relationship for hypofractionated radiotherapy of oligometastases. METHODS: Retrospective analysis of metastases treated by hypofractionated stereotactic radiotherapy was performed. Delivered dose was calculated both as biological effective dose (BED10 ), and as ratio between BED10 and the logarithm of metastasis volume (BED10 logVolume Ratio, BVR)...
September 14, 2018: Medical Oncology
Filippo Pesapane, Marcin Czarniecki, Matteo Basilio Suter, Baris Turkbey, Geert Villeirs
The detection of distant metastases at the initial diagnosis of prostate cancer (PCa) establishes the treatment approach and has a prognostic value, nevertheless it is not well established. Since proposed staging approaches often contradict each other, we aimed to compare the current imaging techniques for staging of advanced PCa, including future applications of the most innovative methods. Conventional imaging techniques, including computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) have been employed for metastatic staging (both N and M staging) of men with high-risk PCa, but surgical pelvic dissection remains the gold standard for N staging...
September 14, 2018: Medical Oncology
Hiroki Ishihara, Satoshi Yamashita, Satoshi Fujii, Kazunari Tanabe, Hirofumi Mukai, Toshikazu Ushijima
Estimation of the cancer cell fraction in breast cancer tissue is important for exclusion of samples unsuitable for multigene prognostic assays and a variety of molecular analyses for research. Here, we aimed to establish a breast cancer cell fraction marker based on DNA methylation. First, we screened genes unmethylated in non-cancerous mammary tissues and methylated in breast cancer tissues using microarray data from the TCGA database, and isolated 12 genes. Among them, four genes were selected as candidate marker genes without a high incidence of copy number alterations and with broad coverage across patients...
September 14, 2018: Medical Oncology
Kathleen Nagle, Barbara Tafuto, Lisa Palladino Kim, J Scott Parrott
Chimeric antigen receptor (CAR) T-cell therapy has shown promise for relapsed/refractory malignancies. Many patients have undergone prior hematopoietic stem cell transplant (HSCT), yet effects of transplant status on CAR T-cell therapy efficacy and safety have not been reported. The purpose of the study is to systematically evaluate the likelihood of achieving optimum response, severe cytokine release syndrome (sCRS), and neurotoxicity in the context of CAR T-cell therapy for HSCT-naïve patients versus those with prior HSCT...
September 11, 2018: Medical Oncology
Priscila da Silva Mendonça, Ronald Pinheiro Feitosa, Silvia Maria Meira Magalhães
No abstract text is available yet for this article.
September 11, 2018: Medical Oncology
In Hee Lee, Keunsoo Kang, Byung Woog Kang, Soo Jung Lee, Woo Kyun Bae, Jun Eul Hwang, Hye Jin Kim, Su Yeon Park, Jun Seok Park, Gyu Seog Choi, Jong Gwang Kim
A good pathologic response to neoadjuvant chemoradiotherapy (CRT) in locally advanced rectal cancer (LARC) is associated with a better prognosis. However, there is no effective method to predict CRT response in LARC patients. Therefore, this study used whole-exome sequencing (WES) to identify novel biomarker predicting CRT benefit in LARC. Two independent tumor tissue sets were used to evaluate the genetic differences between the good CRT response group (15 patients achieved a pathologic complete response (pCR)) and the poor CRT response group (15 patients with pathologic stage III)...
September 11, 2018: Medical Oncology
Noriyoshi Iriyama, Kei-Ji Sugimoto, Eriko Sato, Tomoiku Takaku, Michihide Tokuhira, Tomonori Nakazato, Maho Ishikawa, Hiroyuki Fujita, Isao Fujioka, Yuta Kimura, Norio Asou, Masahiro Kizaki, Norio Komatsu, Yoshihiro Hatta, Tatsuya Kawaguchi
Treatment with a tyrosine kinase inhibitor (TKI) is the standard of care for patients with chronic myeloid leukemia (CML). The new-generation TKIs, nilotinib and dasatinib, are found to have deeper and faster treatment response rates compared to imatinib in the first-line setting. However, a direct comparison between nilotinib and dasatinib has never been reported previously. Our study aims to compare the outcomes and molecular responses achieved following the first-line use of these two agents in patients with CML-CP...
September 7, 2018: Medical Oncology
Winston Chew, Charlotte Benson, Khin Thway, Andrew Hayes, Aisha Miah, Shane Zaidi, Alex T J Lee, Christina Messiou, Cyril Fisher, Winette T van der Graaf, Robin L Jones
BACKGROUND: Sclerosing epithelioid fibrosarcoma (SEF) is a very rare soft tissue sarcoma subtype. Clinically it is an aggressive tumour; however, to our knowledge there are no published reports regarding the efficacy of chemotherapy in SEF. Therefore, the aim of this study was to document the outcome of a series of patients with SEF treated at a single referral centre with reference to systemic therapy. METHODS: A retrospective search of a prospectively maintained database was performed to identify all patients diagnosed with SEF between 1990 and 2017...
September 5, 2018: Medical Oncology
Tarcila Santos Datoguia, Elvira Deolinda Rodrigues Pereira Velloso, Ricardo Helman, Juliane Garcez Musacchio, Marco Aurélio Salvino, Rodolfo Almeida Soares, Marcia Higashi, Adriana Valente Fadel, Rodrigo Santucci Alves E Silva, Nelson Hamerschlak, Fabio Pires de Souza Santos, Paulo Vidal Campregher
Prognostic stratification in acute myeloid leukemia (AML) relies, mostly, on cytogenetics and molecular features of leukemic blasts. The LeukemiaNet prognostic scoring system has been proposed as a standardized way of evaluating prognosis in AML. We have analysed outcomes in 65 AML cases (median age of 54 years, range 18-82) treated at five hematology centers in Brazil stritified according to the European Leukemia Net (ELN) recommendations for cytogenetic and molecular analysis. We classified patients as favorable (N = 13), intermediate-1 (N = 25), intermediate-2 (N = 15), or adverse risk (N = 9)...
September 5, 2018: Medical Oncology
Marina K Ibragimova, Matvey M Tsyganov, Nicolay V Litviakov
The involvement of human papillomavirus in carcinogenesis of colorectal cancer is a contentious issue. The presented meta-analysis was performed to systematize the currently available research results on the matter. The analysis was based on the data from 19 studies to assess the association of HPV infection with colorectal cancer. According to the obtained data, researchers determined the statistically significant level of HPV infection in tumor tissue of CRC and the resulting relative risk of developing CRC with HPV infection to be RR (95% CI) = 2...
September 5, 2018: Medical Oncology
Masato Karayama, Naoki Inui, Kazuki Tanaka, Hideki Yasui, Hironao Hozumi, Yuzo Suzuki, Kazuki Furuhashi, Tomoyuki Fujisawa, Noriyuki Enomoto, Yutaro Nakamura, Takafumi Suda
Aprepitant prevents chemotherapy-induced nausea and vomiting (CINV) in carboplatin-containing chemotherapy. However, it is unknown whether aprepitant salvage therapy after the development of emesis is as effective as adding prophylactic aprepitant to doublet therapy with dexamethasone and a 5-HT3 receptor antagonist from the first cycle of chemotherapy. To compare the antiemetic efficacy of aprepitant between salvage and prophylactic administration in the second cycle of carboplatin-containing chemotherapy, twenty-two NSCLC patients who developed CINV in the first cycle of carboplatin-containing therapy without aprepitant (salvage group) and 44 patients who received aprepitant (prophylaxis group) were extracted from the pooled data of two clinical trials, with adjustment for age, sex, and chemotherapeutic regimen as co-variables using propensity score matching...
September 5, 2018: Medical Oncology
Stephen E Langabeer
No abstract text is available yet for this article.
August 29, 2018: Medical Oncology
Catherine R Garcia, Stacey A Slone, Rachael M Morgan, Lindsey Gruber, Sameera S Kumar, Donita D Lightner, John L Villano
There are limited treatment modalities after high-grade gliomas recurrence. MGMT depletion modulated by dose-dense temozolomide (ddTMZ) remains a debated therapy for initial TMZ responders. Patients were selected retrospectively from our practice with diagnosis of high-grade gliomas (WHO grade III or IV), and were followed since the start of ddTMZ until death or change of therapy. Twenty-one patients were reviewed, with a median age of 47 (25-61) years and a median of 5.8 (1.5-38.8) cycles of ddTMZ. The majority were males (71...
August 28, 2018: Medical Oncology
Martina Zacher, Markus V Heppt, Titus J Brinker, Kinan M Hayani, Michael J Flaig, Carola Berking
Sarcomas are a heterogeneous group of mesenchymal tumors which can affect bone and soft tissue. Leiomyosarcoma (LMS) is a rare subtype localized to the skin or subcutaneous tissue. Due to the heterogeneity of sarcomas, reviews and guidelines with an in-depth focus specifically on primary LMS of the skin are sparse. This article is intended to provide an up to date and systematic overview on diagnosis, treatment, and surveillance of this rare entity to provide a framework for decision making and management for dermato-oncologists...
August 23, 2018: Medical Oncology
Hideaki Miyake, Yuto Matsushita, Hiromitsu Watanabe, Keita Tamura, Takahisa Suzuki, Daisuke Motoyama, Toshiki Ito, Takayuki Sugiyama, Atsushi Otsukav
The objective of this study was to investigate the significance of an alternative dosing schedule for sunitinib in metastatic renal cell carcinoma (mRCC) patients. This study included 154 patients treated with sunitinib as first-line systemic therapy for mRCC, consisting of 62, 47, and 45 receiving sunitinib based on a traditional schedule (TS, 4 weeks on and 2 weeks off) alone (TS group), alternative schedule (AS, 2 weeks on and 1 week off) alone (AS group), and TS followed by AS after the development of dose-limiting toxicities (TS-to-AS group), respectively...
August 20, 2018: Medical Oncology
Guillaume Klausner, Eivind Blais, Raphaël Jumeau, Julian Biau, Mailys de Meric de Bellefon, Mahmut Ozsahin, Thomas Zilli, Raymond Miralbell, Juliette Thariat, Idriss Troussier
The best curative option for locally advanced (stages II-III) squamous-cell carcinomas of the anal canal (SCCAC) is concurrent chemo-radiotherapy delivering 36-45 Gy to the prophylactic planning target volume with an additional boost of 14-20 Gy to the gross tumor volume with or without a gap-period between these two sequences. Although 3-dimensional conformal radiotherapy led to suboptimal tumor coverage because of field junctions, this modality remains a standard of care. Recently, intensity-modulated radiotherapy (IMRT) techniques improved tumor coverage while decreasing doses delivered to organs at risk...
August 20, 2018: Medical Oncology
Melissa Bersanelli, Matteo Brighenti, Sebastiano Buti, Sandro Barni, Fausto Petrelli
Immune checkpoint inhibitors (CKIs) are therapeutic weapons in several advanced malignancies. Performance status is a validated prognostic variable in cancer patients; it possibly affects the efficiency of the immune system. We performed a systematic review and meta-analysis to investigate the predictive role of PS toward treatment with CKIs in cancer patients. Following PRISMA guidelines, an electronic search from PubMed, The Cochrane Library and Embase was performed, from the inception of each database to May 31, 2018...
August 20, 2018: Medical Oncology
Alexandra Pender, Elizabeth J Davis, Dharmisha Chauhan, Christina Messiou, Omar Al-Muderis, Khin Thway, Cyril Fisher, Shane Zaidi, Aisha Miah, Ian Judson, Winette van der Graaf, Vicki L Keedy, Charlotte Benson, Robin L Jones
The outcome for patients with unresectable or metastatic soft tissue sarcoma remains poor with few treatment options. Synovial sarcoma is a rare type of sarcoma, predominantly affecting adolescents and young adults. Following failure of first-line anthracycline-based chemotherapy, several salvage options are available. We reviewed the safety and efficacy of gemcitabine/docetaxel chemotherapy in two tertiary oncology centres. We identified patients treated with gemcitabine/docetaxel between 2004 and 2016 in a UK and a US oncology centre using retrospective pharmacy and medical records...
August 20, 2018: Medical Oncology
Zhifeng Lin, Liwen Xiong, Qiang Lin
No abstract text is available yet for this article.
August 18, 2018: Medical Oncology
Xiwei Liu, Li Min, Hong Duan, Rui Shi, Wenli Zhang, Song Hong, Chongqi Tu
No abstract text is available yet for this article.
August 17, 2018: Medical Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"